FDA to Require Additional Warnings for JAK Inhibitors Treating Select Chronic Inflammatory Conditions

FDA will now require new and updated warnings about the increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions.